PRINCETON, N.J., Oct. 28 /PRNewswire-FirstCall/ -- Bristol-Myers Squibb Company today announced the appointment of Elliott Sigal, M.D., Ph.D., to chief scientific officer and president of the company's Pharmaceutical Research Institute (PRI).
"Elliott is an outstanding leader and an exceptional scientist," said Peter R. Dolan, chairman and chief executive officer. "He has an impressive depth of experience in all stages of research and development. From discovery, through exploratory and full development, to regulatory approval, Elliott has demonstrated his expertise at moving compounds through the pipeline and bringing them to market."
Dr. Sigal joined Bristol-Myers Squibb in November 1997 as vice president, Applied Genomics. In October 1999, Dr. Sigal became senior vice president for Early Discovery and Applied Technology. He was named head of Drug Discovery and Exploratory Development in January 2001 and he was named to the Bristol-Myers Squibb Executive Committee that same year. In January 2002, Dr. Sigal was appointed Bristol-Myers Squibb's senior vice president of Global Clinical and Pharmaceutical Development.
Under his leadership of the development organization, three new medicines came to market: Abilify, Reyataz and Erbitux. In addition, he led the full development of three new medicines the company plans to submit this year to the U.S. Food and Drug Administration (FDA) for approval: entecavir, muraglitazar and abatacept. The company has already submitted a new drug application for entecavir with both the FDA and European regulatory authority.
"Dr. Sigal worked hand-in-hand with Dr. James Palmer, the company's chief scientific officer who died earlier this week," Mr. Dolan added. "Among Dr. Palmer's many contributions to the company was developing a successor who was ready to take over the leadership of the PRI."
Dr. Sigal has more than 20 years of combined experience in medicine, research and management. He received his medical degree from the University of Chicago in 1981 and trained in Internal Medicine and Pulmonary Medicine at the University of California, San Francisco (UCSF). His research training was received at the Cardiovascular Research Institute at UCSF. Dr. Sigal served on the faculty of the UCSF Department of Medicine from 1988 to 1992. He joined the pharmaceutical company Syntex in 1992 and held positions of increasing responsibility in drug discovery. In September 1995, Dr. Sigal joined the genomics firm Mercator Genetics as Vice President of Research and Development. Prior to medical school he studied engineering and management at Purdue University where he received a B.S., M.S., and Ph.D.
Bristol-Myers Squibb Company is a global pharmaceutical and related health care products company whose mission is to extend and enhance human life.
Bristol-Myers Squibb Company
CONTACT: Rob Hutchison, +1-609-252-3901, email@example.com,Corporate Affairs, or John Elicker, +1-212-546-3775, firstname.lastname@example.org,Investor Relations, both of Bristol-Myers Squibb Company